Evolocumab in Patients without a Previous Myocardial Infarction or Stroke

202531 citationsJournal Article

Authors

Erin A. Bohula · Thrombolysis in Myocardial Infarction Study Group

Nicholas Marston · Thrombolysis in Myocardial Infarction Study Group

Ajay Bhatia · Amgen (United States)

Gaetano Maria De Ferrari · Azienda Ospedaliera Citta' della Salute e della Scienza di Torino

Lawrence A. Leiter · St. Michael's Hospital

José Carlos Nicolau · Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

Abstract

PCSK9 inhibition with evolocumab led to a lower risk of first cardiovascular events than placebo among patients with atherosclerosis or diabetes and without a previous myocardial infarction or stroke. (Funded by Amgen; VESALIUS-CV ClinicalTrials.gov number, NCT03872401.).

Topics & Keywords

Lipoproteins and Cardiovascular Health Cerebrovascular and Carotid Artery Diseases Atherosclerosis and Cardiovascular Diseases

Publication Details

Published in: New England Journal of Medicine

Volume 394, Issue 2, pp. 117-127

DOI: 10.1056/nejmoa2514428

Field-Weighted Citation Impact: 60.66

Command Palette

Evolocumab in Patients without a Previous Myocardial Infarction or Stroke

Authors

Abstract

Topics & Keywords

Publication Details